Healthy Future Sask Launch!!

Congratulations to our colleagues at Healthy Future Sask!! With the addition of Healthy Futures Sask, CanPath is represented by regional cohorts in all ten provinces. CanPath is the largest population health cohort study in the country with more than 330,000 participants. Healthy Future Sask will be recruiting 7,000 provincial participants between the ages of 30-74. “Adding Saskatchewan to this major research project is an opportunity to be part of creating a legacy with wide-ranging impacts for generations to come,” said Riaz Alvi, Scientific Director for Healthy Future Sask and Director of Epidemiology for the Saskatchewan Cancer Agency. “The information within our cells can be a valuable asset towards scientific and global research while enhancing the research already being done and supported at the Saskatchewan Cancer Agency. In addition, this study will allow researchers to use more fulsome data to understand the risks for chronic disease, including cancer.” For additional details, please visit: https://canpath.ca/2023/02/healthy-future-sask-public-launch/

CanPath Announces its 2023-2027 Strategic Plan

The Canadian Partnership for Tomorrow’s Health (CanPath) is excited to announce its 2023-2027 Strategic Plan! The four key objectives of this plan will guide CanPath’s work over the next four years: Expand the cohort by engaging more participants from underrepresented populations and identifying partners in regions not yet included Enrich the cohort by linking CanPath data with data from provincial data holders and registries and collecting more longitudinal data Transform the cohort by turning existing biosamples into data, collecting serial biosamples, and enhancing access to CanPath’s harmonized data Engage with key audiences and stakeholders, further enabling the participants’ voices, and enhancing awareness of CanPath on national and international levels Thank you for supporting our shared vision for a world without chronic disease and cancer. We extend our warmest thanks to our participants, researchers, and funders for all their contributions to population health. With your support, we have been solving some of the biggest health challenges in Canada since 2008! The team is excited to be taking these new steps forward following CanPath’s exciting achievements over the past few years, such as: Establishing a renewed governance model including the formation of a National Coordinating Centre at the University of Toronto in 2019; oversight and leadership roles were established or renewed, such as the National Strategic Advisory Council and the International Scientific Advisory Board Launching its first follow-up questionnaire in 2016; over 120,000 CanPath participants completed this questionnaire over the course of three years, providing updated information on their health and new information related to mental health and the use of marijuana, e-cigarettes, and over-the-counter drugs Responding quickly to the COVID-19 pandemic in 2020 by leveraging its existing infrastructure to support national research Supporting over 250 research projects and 200 publications in research areas including arthritis, cancer, diabetes, respiratory disease, heart disease, and more! While the 2017-2022 Strategic Plan aspired to leverage CanPath’s assets to achieve optimal cohort value, this new 2023-2027 plan aims to expand and enrich the platform while promoting CanPath’s key contributions to the Canadian health research landscape. To learn more about some of CanPath’s research achievements over the years, check out this video on how CanPath data enables scientific discoveries. The full Strategic Plan can be downloaded at https://canpath.ca/2023/01/2023-2027-strategic-plan/.

Nearing PhD Defense

Congratulations to Jacob Nearing who successfully defended his PhD in Microbiology and Immunology at Dalhousie University!! Supervised by Dr. Morgan Langille, Jacob used biosamples from Atlantic PATH and Alberta’s Tomorrow Project in his work, “Identification of Robust Biomarkers Using Microbiome DNA Sequencing with a Focus on the Oral Microbiome and Cancer Associations.” Abstract The human microbiome can be defined as the community of microbes that live within and on the human body. Modern day microbiome research relies on the use of high throughput deoxyribonucleic acid (DNA) sequencing to characterize and identify microbes and community structures associated with human disease. Indeed, the human microbiome has been proposed as a useful source of biomarkers for numerous human health conditions including cancer. Yet often, microbial biomarkers identified through DNA sequencing efforts are not reproducible between studies. Herein, I present my work on examining computation choices during microbiome experiments and applying this knowledge to identify novel associations with the salivary microbiome and breast, prostate, and colon cancer. Typical DNA sequenced based surveys of microbiomes, requires numerous choices to be made at each step of the experimental protocol. Often theses choices are unclear with no current gold standard within the field. Yet, these methods are used interchangeable within the literature without regard for how that choice might impact the biological conclusions that researchers find. To help address this issue I examined how choices made during two computational steps for processing DNA sequencing data impacted the biological conclusions drawn. In doing so I highlighted critical differences that can be attributed to bioinformatic tool choice and suggest potential solutions for these issues in the future. Using information from the above chapters, the second half of this thesis represents analysis done on salivary samples from a large population cohort to both characterized salivary microbiome variation and how that variation is associated with breast, prostate, and colon cancer. Within these chapters we show that several daily life factors are significantly associated with salivary microbiome composition, yet they only explain a small amount of total community variance. We also show that the salivary microbiome contains little signal in cases of breast and prostate cancer. Contrastingly our work did show potential salivary microbiome associations within cases of colon cancer. These findings show the potential for future diagnostic research into the relation between the oral microbiome and colon cancer development. Jacob’s publications and additional information about his research can be found here. Congratulations, Dr. Nearing!! We wish you all the best in the future and look forward to following your career.  

Canadian Cancer Society Accelerator Grants

The Canadian Cancer Society’s Accelerator grants seek to accelerate the application of high-quality evidence addressing unmet, cancer-related needs (bit.ly/3B9DTj5). Congratulations to Dr. Robin Urquhart, Scientific Director of Atlantic PATH and Dr. Trevor Dummer, National Scientific Co-Director of CanPath on their successful Accelerator grants! Dr. Urquhart’s work will focus on adapting and implementing cancer patient pathways in Nova Scotia. The overarching aim is to implement and test evidence-based Cancer Patient Pathways as a coordinated approach to referral and early diagnosis is needed t oreduce delays and improve patient outcomes. Dr. Dummer’s work will focus on preventing cancer in the gender minority populations. While existing cancer prevention strategies address the needs of the majority population quite well, alternate strategies that account for the needs of marginalized communities who are often at an increased risk of cancer are lacking. This work will synthesize existing practice and is related to Dr. Dummer’s current CanPath project, “Primary Prevention of Cancer-Causing Substance Use in Gender Minority People of Canada” (https://canpath.ca/project/dummer-chan-2022/).

2022 Women Leaders in Digital Health

Congratulations to our colleague, Dr. Samina Abidi who has been selected as one of nine Women Leaders in Digital Health 2022 by Digital Health Canada. Launched in 2017, this award recognizes visionaries who are harnessing the power of IT to transform Canadian health and healthcare. Dr. Abidi is an Associate Professor in the Department of Community Health and Epidemiology, Faculty of Medicine at Dalhousie University. She holds an MD, MSc in Information Technology and PhD in Health Informatics. Dr. Abidi is the co-Director of the NICHE (kNowledge Intensive Computing for Healthcare Enterprises) research group and has been involved with digital health academics, innovation, mentorship and advocacy for over 10 years. Her research interests span artificial intelligence, digital health and knowledge management. “… [G]iven the unique challenges and demands faced by the Canadian health system, we need not just dynamic clinical leaders but also a diversified community of thinkers and problem solvers who bring innovative solutions to address the gaps within the Canadian health system. In this regard, Dr. Abidi possesses excellent leadership, innovation, forward-thinking and interpersonal skills, coupled with sound academic acumen and experience that is helping to improve the Canadian health system.” https://digitalhealthcanada.com/news/2022-women-leader-samina-r-abidi/        

Prostate Cancer Awareness Month Logo

CanPath Research Round-Up: Prostate Cancer Awareness

For September 2022’s #ProstateCancerAwarenessMonth, we shared insights across our social media channels from prostate cancer studies by CanPath researchers. Thanks to rich data from over 330,000 volunteer participants and researchers’ efforts, we can help change the future of prostate cancer! CanPath’s Research Round-Up highlights work on prostate cancer from Atlantic PATH and collaborators using our questionnaire data and toenail samples! https://canpath.ca/2022/11/prostate-cancer-awareness-month/  

Prostate Cancer Awareness Month

This #ProstateCancerAwarenessMonth, we’re sharing insights from recent studies from researchers across Canada. Today, we’re sharing findings from Sheida Majouni, PhD candidate from Dalhousie University! In 2022, Majouni and colleagues applied machine learning to arsenic species and metal profiles of toenails from Atlantic PATH. They aimed to understand environmental metal’s potential to produce disease, specifically prostate cancer: https://bit.ly/3eVjUMK “Artificial intelligence has a unique potential to revolutionize population health,” says Dr. Syed Sibte Raza Abidi, Professor in the Faculty of Computer Science at Dalhousie University. “By discovering environmental risk factors’ influence on chronic disease risk with risk prediction models, it is a pivotal tool for mitigating the risk of chronic disease onset.” This work is being expanded with the support of a New Frontiers in Research Fund (NFRF) Exploration grant. Team members include Dr. Syed Sibte Raza Abidi (Nominated Principal Investigator), Dr. Jong Sung Kim (Co-Principal Investigator), Dr. Ellen Sweeney (Co-Investigator), Dr. Gabriela Ilie (Co-Investigator), Dr. Trevor Dummer (Co-Investigator), Dr. Taehyun Roh (Collaborator), Dr. Nathalie Saint-Jacques (Collaborator), and Jason Hicks (Collaborator). Watch this space for future findings!

Prostate Cancer Awareness Month

This #ProstateCancerAwarenessMonth, we’re sharing insights from recent studies from researchers across Canada. Today, we’re sharing findings from Gabriela Ilie, PhD, associate professor at Dalhousie University and DMRF Endowed Scientist in Cancer Quality of Life Research! In 2019, Dr. Gabriela Ilie, Dr. Rob Rutledge and Dr. Ellen Sweeney examined the association between depression and anxiety and prostate cancer. From 6,585 Atlantic PATH participants, they found that prostate cancer survivors had greater odds of screening positive for anxiety or depression compared to those with a history of other forms of cancer. The findings highlight the importance of a multidisciplinary effort to prioritize and deliver comprehensive mental health support to PCa survivors: https://bit.ly/3Dqe6oH Come 2021, they continued their work in the area of depression, anxiety and prostate cancer, further finding that the association is moderated by household income: https://bit.ly/3B9D0X3 They most recently found that prostate cancer survivors who were treated with surgery had 7.55 statistically significantly higher odds of screening positive for current depression compared to those who had surgery for other types of cancer: https://bit.ly/3S4EQPT “This pivotal research made possible by Atlantic PATH and its collaborators highlights the epidemic of mental distress among prostate cancer survivors throughout Atlantic Canada, now corroborated worldwide. This research became the impetus for development of the PC-PEP program (https://pcpep.org/) which is now helping survivors throughout Canada and beyond,” says Dr. Ilie.  

Applying Machine Learning to Arsenic Species and Metallomics Profiles of Toenails to Evaluate Associations of Environmental Arsenic with Incident Cancer Cases

Authors: Sheida Majouni, Jong Sung Kim, Ellen Sweeney, Erin Keltie, Syed Sibte Raza Abidi Ebook: Volume 294: Challenges of Trustable AI and Added-Value on Health Abstract: Chronic exposure to environmental arsenic has been linked to a number of human diseases affecting multiple organ systems, including cancer. The greatest concern for chronic exposure to arsenic is contaminated groundwater used for drinking as it is the main contributor to the amount of arsenic present in the body. An estimated 40% of households in Nova Scotia (Canada) use water from private wells, and there is a concern that exposure to arsenic may be linked to/associated with cancer. In this preliminary study, we are aiming to gain insights into the association of environmental metal’s pathogenicity and carcinogenicity with prostate cancer. We use toenails as a novel biomarker for capturing long-term exposure to arsenic, and have performed toxicological analysis to generate data about differential profiles of arsenic species and the metallome (entirety of metals) for both healthy and individuals with a history cancer. We have applied feature selection and machine learning algorithms to arsenic species and metallomics profiles of toenails to investigate the complex association between environmental arsenic (as a carcinogen) and prostate cancer. We present machine learning based models to ultimately predict the association of environmental arsenic exposure in cancer cases. doi: https://ebooks.iospress.nl/doi/10.3233/SHTI220385